

This carbon reduction plan has been completed in accordance with PPN 06/21.



- Commitment to achieving Net Zero
- O2 Baseline Emissions Footprint
- OZ Current Emissions Reporting
- Emissions Reduction Targets
- Carbon Reduction Projects
- **06** Declaration and Sign Off

COMMITMENT TO ACHIEVING NET ZERO

Techdow Pharma England is committed to achieving Net Zero emissions by 2050.

BASELINE EMISSIONS FOOTPRINT

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions.

Baseline emissions are the reference point against which emissions reduction can be measured.

BASELINE YEAR 2022

Baseline Year: 2022	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	0
Scope 2	0.7
Scope 3	6,841.1
(Included Sources) 1 Purchased goods & services 2 Capital goods 3 Fuel & energy related activities 4 Upstream transportation & distribution 5 Waste treatment 6 Business travel 7 Employee commuting & homeworking 8 Upstream leased assets 9 Downstream transportation & distribution 10 Processing of sold products 11 Use of sold products 12 End of life treatment 13 Downstream leased assets	6,722.5 0.6 0 44.4 0.1 16.8 4.5 0 6.1 0 0 46.1
Total Emissions	6,841.8

Additional Details relating to the Baseline Emissions calculations

Original baseline for 2022 was generated using two publicly available emission calculators; the GHG Protocol Scope 3 Evaluator by Quantis and the Carbon Footprint Calculator for UK Businesses by SSE. The Scope 3 Evaluator was decommissioned in August 2023 due to increasingly obsolete technological compatibility and calculating assumptions.

Therefore, Techdow Pharma England engaged the services of Carbon Zero, a division of Data Projects Limited, to verify baseline emissions for 2022. GHG Protocol standards, PAS 2060 and ISO 14064 standards were applied by Carbon Zero during their assessment, with UK Government GHG and BEIS conversion factors for 2022 taken into account.

The original baseline calculation was a total of $17,466.5 \, \text{tCO}_{2}\text{e}$, with over 99% of emissions falling within Scope 3. The recalculation of baseline found that 2022 emissions were $6,841.8 \, \text{tCO}_{2}\text{e}$ but verified that over 99% of emissions fell within Scope 3.

Using the principles of emissions intensity, this has been normalised to 160 Kg/CO₂e per £1,000 of turnover in 2022.



CURRENT EMISSIONS REPORTING

Reporting Year: 2023	
EMISSIONS	TOTAL (tCO2e)
Scope 1	0
Scope 2	2.21
Scope 3	7,386.81
(Included Sources) 1 Purchased goods & services 2 Capital goods 3 Fuel & energy related activities 4 Upstream transportation & distribution 5 Waste treatment 6 Business travel 7 Employee commuting & homeworking 8 Upstream leased assets 9 Downstream transportation & distribution 10 Processing of sold products 11 Use of sold products 12 End of life treatment 13 Downstream leased assets	7036.81 0.614 1.036 60.754 0.043 37.514 2.666 0 196.092 0 0 51.272
Total Emissions	7,389.02

Additional Details relating to the Reporting Emissions calculations

Emissions in 2023 were 104 Kg/CO2e per £1,000 of turnover.


Over 99.9% of emissions for Techdow Pharma England in 2023 fell within Scope 3.



In order to continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets, with the key target based on emissions intensity:


- 1 Reduce Scope 3 intensity emissions by 18.5% by 2028
- 2 Maintain Scope 1 emissions at 0 tCO₂e
- Reduce Scope 2 emissions to 2 tCO₂e by 2025

We project that carbon emissions will decrease over the next five years to 125.68 Kg/CO₂e per £1,000 of turnover by 2028. This is a reduction of 18.5%. However, emissions in 2023 were below projected values.



Progress against the stated targets can be seen in the graph below:





COMPLETED CARBON REDUCTION INITIATIVES

The following environmental management measures and projects have been completed or implemented since the 2022 baseline. The carbon emission reduction achieved by these schemes equate to 1.891 tCO₂e, a 0.028% reduction against the 2022 baseline and the measures will be in effect when performing the contract.

- Sustainability training was rolled out to all employees in 2023, which helped to improve Scope 3 emissions related to subsections 5 and 7 (home working & commuting and office wastage). This achieved a reduction of tCO2e 1.891, which although modest when considered against the total 2022 baseline (0.028% reduction), represented a 60% reduction in emissions specifically related to Scope 3 subsections 5 and 7.
- The existing Techdow products are equipped with a polypropylene needle shield device. An alternative needle shield device was trialled by Techdow Pharma England in 2023. While the alternative device used less plastic and was lighter than the current device (potentially equating to more efficient transportation and lower volumes of plastic waste), the alternative device was not well received by potential users and plans had to be shelved.
- Initial sustainability audits of our downstream suppliers have been completed and are in progress for our upstream suppliers.



COMPLETED CARBON REDUCTION INITIATIVES

In the future we hope to implement further measures such as:

- Our manufacturer of finished goods has prepared a second needle shield alternative device to be trialled in 2024. If successful, the annual footprint for purchased goods could be reduced by 105.3 tCO₂e, compared to the 2022 baseline.
- Following initial sustainability audits of our upstream and downstream suppliers, we are now actively engaging our supplier and partners regarding their emissions reduction initiatives:
 - Downstream transportation and distribution is the second largest source of emissions for Techdow Pharma England. Our distribution partner is currently trialling an electric vehicle fleet and is increasing their capacity for onsite electricity generation, primarily from solar sources.
 - Our landlord purchases energy from renewable sources and has a programme to generate a significant proportion of required energy from onsite sources, such as solar electric car charging sites and solar farming.
- While there has been success with reducing employee commuting and office wastage, further initiatives such as a travel management policy to reduce business air travel are planned. This could give a potential reduction in annual emissions of 5.4 tCO₂e.

DECLARATION AND SIGN OFF

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standards for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off by the Techdow Pharma England board of directors.

Date: 26th February 2024

Signed on behalf of the Supplier:

Paula George

Signature:

Paula George, Managing Director Techdow Pharma England Limited